OpenAI has partnered with Retro Biosciences, a longevity science startup, to develop GPT-4b micro, an AI model designed to engineer proteins that could extend human lifespan.
Retro Biosciences, founded by Joe Betts-LaCroix, focuses on extending human lifespan by 10 years through advancements in biotechnology.
This collaboration reflects a broader trend of significant investments in the longevity sector by tech industry leaders. For instance, Sam Altman, CEO of OpenAI, has invested $180 million into Retro Biosciences.
Similarly, Jeff Bezos has invested in Altos Labs, a company dedicated to life extension research.
While these developments hold promise, they also raise ethical and societal considerations, such as equitable access to life-extending technologies and the implications of increased human longevity. The longevity research field faces challenges, including regulatory hurdles, ethical questions, and the need to address environmental factors affecting life expectancy.
